Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen

July 29, 2024 6:16 AM

The European Union's (EU) drug regulator has rejected Eisai and Biogen's (NASDAQ: BIIB) Leqembi treatment for early Alzheimer's disease, citing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found